Key result
COVID-19 mRNA vaccines cause myopericarditis in adolescent males at lower rates than SARS-CoV-2 infection.
Why the study?
Myopericarditis can occur as an adverse effect of COVID-19 mRNA vaccination, with refractory cases having a limited evidence base to guide management.
Answers are grounded in this paper and cite their sources.
COVID-19 mRNA vaccines are associated with a rare risk of myopericarditis, particularly in adolescent males after the second dose, but the risk remains significantly lower than that associated with SARS-CoV-2 infection.
Globally, vaccination against COVID-19 has prevented countless infections, hospitalisations and death and represents the most successful intervention in combating the pandemic caused by SARS-CoV-2 infection. Utilisation of existing mRNA vaccine technology has allowed for rapid development of highly immunogenic and effective vaccines. Myopericarditis can occur as an adverse effect of COVID-19 mRNA vaccination, albeit at significantly lower rates than those that occur during SARS-CoV-2 infection. Higher rates are seen in adolescent males, usually within 1-5 days of receiving the second vaccine dose. Although most cases are self-limited and respond to first-line treatment, refractory cases can occur, with a limited evidence base on which to guide management. Here, we present a brief review of COVID-19 mRNA vaccines and associated myopericarditis including risk factors, proposed mechanism, and treatment including management strategies for refractory disease.
No takes yet. Share an insight, caveat, or question.
Gnanenthiran et al. (2022) conducted a review in COVID-19 mRNA vaccine-associated myopericarditis. COVID-19 mRNA vaccines was evaluated. COVID-19 mRNA vaccination can cause myopericarditis, with higher rates in adolescent males 1-5 days post-second dose, though at significantly lower rates than during SARS-CoV-2 infection.
Synapse has enriched 10 related papers. Consider them for comparative context: